Suchergebnisse - "Engelhardt, Monika"

PubPharm (22)

1

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

2

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma : a study on behalf of the Chronic malignancies working party of the EBMT

enthalten in: Bone marrow transplantation | 2023

von Tilmont, R. | Yakoub-Agha, I. | Eikema, D. | +23

3

Carfilzomib, lenalidomide, and dexamethasone maintenance for multiple myeloma : when and for whom?

enthalten in: The Lancet. Oncology | 2023

von Engelhardt, M. | Wäsch, R.

CommentOn: Lancet Oncol. 2023 Feb;24(2):139-150. - PMID 36642080

4

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristics

enthalten in: European journal of haematology | 2022

von Richardson, P. | Schjesvold, F. | Weisel, K. | +25

5

Expert review on soft-tissue plasmacytomas in multiple myeloma : definition, disease assessment and treatment considerations

enthalten in: British journal of haematology | 2021

von Rosiñol, L. | Beksac, M. | Zamagni, E. | +35

6

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM) : outcomes by prior treatment at first relapse

enthalten in: Leukemia | 2021

von Dimopoulos, M. | Weisel, K. | Moreau, P. | +17

7

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma : a first-in-human, multicentre, phase 1-2a trial

enthalten in: The Lancet. Haematology | 2020

von Raab, M. | Engelhardt, M. | Blank, A. | +15

8

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Haematology | 2019

von Usmani, S. | Schjesvold, F. | Oriol, A. | +115

CommentIn: Lancet Haematol. 2019 Sep;6(9):e439-e440. - PMID 31327688

9

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2019

von Richardson, P. | Oriol, A. | Beksac, M. | +123

CommentIn: Lancet Oncol. 2019 Jun;20(6):743-744. - PMID 31097404

10

GFR estimation in lenalidomide treatment of multiple myeloma patients : a prospective cohort study

enthalten in: Clinical and experimental nephrology | 2019

von Schmidts, A. | Grünewald, J. | Kleber, M. | +7